Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Small-cap equities have entered a secular outperformance regime backed by accelerating EPS growth and 25-year valuation lows relative to large caps. While speculative, unprofitable stocks temporarily led the initial surge, disciplined exposure to profitable, low-volatility quality growth compounders provides the superior risk-adjusted vehicle for the decade ahead.
Full Quick Take
Small-cap equities have entered a secular outperformance regime backed by accelerating EPS growth and 25-year valuation lows relative to large caps. While speculative, unprofitable stocks temporarily led the initial surge, disciplined exposure to profitable, low-volatility quality growth compounders provides the superior risk-adjusted vehicle for the decade ahead.
TimesSquare's Mid Cap Growth Strategy outperformed its index in 3Q25 with a 5.28% net return. The firm maintains a disciplined, fundamental-focused approach, actively managing risks around speculative AI spending and high-beta market rotations.
Full Quick Take
TimesSquare's Mid Cap Growth Strategy outperformed its index in 3Q25 with a 5.28% net return. The firm maintains a disciplined, fundamental-focused approach, actively managing risks around speculative AI spending and high-beta market rotations.
Polen Focus Growth experienced a relative performance drag in Q2 2025 due to zero exposure to soaring semiconductors, but nimbly capitalized on market volatility to add to high-conviction compounders like Adobe and IDEXX.
Full Quick Take
Polen Focus Growth experienced a relative performance drag in Q2 2025 due to zero exposure to soaring semiconductors, but nimbly capitalized on market volatility to add to high-conviction compounders like Adobe and IDEXX.
